

Out. number: 194-00-3/20.01.2023

Publication of the Tender offering addressed to the shareholders of “Sopharma” AD by “Donev Investments Holding” AD and Opinion of the Board of Directors in connection with Art. 154 of the Law on Public Offering of Securities and Art. 36 of Ordinance 13 of 22.12.2003 on tender offerings for purchase and exchange of shares

Sofia, Bulgaria, January 20, 2023 - Pursuant to the requirements of Art. 154, para. 1 of the Law on Public Offering of Securities, the Board of Directors of “**Sopharma**” AD (SFA: BSE, SPH: Warsaw Stock Exchange) notifies that on 19.01.2023 the Financial Supervision Commission took a decision not to issue a final prohibition on the publication of a tender offering registered with the Financial Supervision Commission by "Donev Investments Holding" AD - a shareholder directly owning 37 600 000 ordinary, dematerialized shares with voting rights, representing 27.89% of the capital and votes in the General Meeting of Shareholders of “Sopharma” AD, pursuant to Art. 149b of the Law on the Public Offering of Securities for the purchase of shares from the remaining shareholders of “Sopharma” AD.

In connection with the above and in fulfillment of the Company's obligations under Art. 154 of the Law on Public Offering of Securities and Art. 36 of Ordinance 13 of 22.12.2003 on tender offerings for purchase and exchange of shares, we publish the final tender offering and the opinion of the Board of Directors of Sopharma AD.



Pelagia Viatcheva
Investor Relations Director

Information about the company

Sopharma AD

Nearly 90 years of tradition and modernity - contemporary production, European standards and quality, best practices in the field of corporate and social responsibility.

Sopharma AD is the most successful Bulgarian company after the privatization, as from 2000 to today, the company realized 10 times growth in market capitalization and 25 times revenue growth. Over the past 10 years, Sopharma AD has been a leader in the pharmaceutical sector in Bulgaria.

Sopharma AD produces active substances and medicinal products; conducts activities related to development and implementation in the field of phytochemistry, chemistry and pharmacy, provides services related to production and other.

With 8 pharmaceutical plants in the country and the only ampoule factory in Bulgaria the company produces 3 billion tablets, 20 million syrup forms, has an authorization for over 200 generic products, 15 traditional products, 12 of which are plant-based, and uses more than 1500 tons of medicinal plants in its products.

Sopharma AD has an active and key role in raising the standard of living, in making people healthier, happier and protected. Sopharma AD is constantly investing in new technologies, innovations and research. The company maintains a dialogue with all players in the pharmaceutical industry and strives to contribute to improving the healthcare sector.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important health related sectors such as pharmaceuticals, hospital supplies, pharmaceutical products distribution and many others. "Sopharma" AD and its production subsidiaries have 8 pharmaceutical plants in Bulgaria, complying with the requirements of EU- GMP.